Regulus' MicroRNA Approach May Hold Key To 4-Week HCV Cure

RG-101 tested in combination with Gilead's Harvoni and two other direct-acting antivirals approved for hepatitis C shows the ability to cure chronic HCV infections with a four-week therapeutic regimen.